Caribou Biosciencesは、5月13日に開催されたBank of Americaグローバルヘルスケアカンファレンスにおいて、同社の既製品（オフ・ザ・シェルフ）型CAR-T療法に関する進捗状況について説明した。レイチェル・ハウウィッツ最高経営責任者（CEO）は、リンパ腫および多発性骨髄腫を対象とした2つのプログラムに関する第I相臨床試験のデータを強調した。
同社は、リンパ腫を対象にCD19を標的とするVispa-celと、多発性骨髄腫を対象にBCMAを標的とするCB-011の開発を進めている。アナリストのアレック・ストラナハン氏が司会を務めたセッションの中で、ハウウィッツ氏は、両プログラムともに昨年末に重要な臨床データが報告されており、初期の結果はクラス最高レベル（ベスト・イン・クラス）の可能性を裏付けるものだと述べた。
AIによるレポート AIによって生成された画像
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.
AIによるレポート
AbCellera Biologics Inc. has released a slide deck related to its fourth-quarter 2025 results. The presentation accompanies the company's earnings call. It was published on February 24, 2026.
Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.
AIによるレポート
Scientists from ITQB NOVA and the Portuguese Institute of Oncology have started the BRIDGE project to uncover how aggressive breast cancer evades the immune system. The initiative seeks biomarkers for better prediction of disease progression and personalized treatments. Funded with up to €75,000, the two-year effort uses patient samples to validate lab findings.
A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.
AIによるレポート
Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.